Removal of Prior Authorization for Hepatitis C Treatment

From MDHHS: For Complete Post, Click Here…

ngd- Bout Time…

The Michigan Department of Health and Human Services (MDHHS) is removing administrative barriers to improve access to a hepatitis C virus (HCV) treatment for program beneficiaries. This policy is part of the MDHHS We Treat Hep C Initiative to eliminate HCV in Michigan.

Effective April 1, 2021, the product MAVYRET® (glecaprevir/pibrentasvir) will no longer require clinical prior authorization (PA) when prescribed in accordance with Food and Drug Administration (FDA)-approved labeling.

This includes removal of the requirement that HCV medications must be prescribed by or in consultation with a hepatologist, gastroenterologist, or infectious disease specialist. All providers who have prescriptive
authority will be able to prescribe this treatment to their patients with HCV.

Leave a Reply